Monitoring the efficiency of iron chelation therapy: The potential of nontransferrin-bound iron

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 94-99

  Hider, R C ^a   Silva, A M N ^a   Podinovskaia, M ^b   Ma, Yongmin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

fluorescent reagent; nontransferrin bound iron

Indexed keywords

ALBUMIN; CARBOXYLIC ACID; CITRIC ACID; FERRIC CITRATE; FERRITIN; FLUORESCENT DYE; GLUTATHIONE; PHOSPHATE;

ATOMIC EMISSION SPECTROMETRY; BINDING AFFINITY; CONFERENCE PAPER; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GEL FILTRATION; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; MEASUREMENT; PRODUCTIVITY;

EID: 77955914915     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05573.x     Document Type: Conference Paper

References (17)

1. Neufeld, E.J. 2006. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassaemia major: new data, new question. Blood 107: 3436-3441
2. Jacobs, E.M.G., J.C.M. Hendriks, B.L.J.H. van Tits, et al. 2005. Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341: 241-250.
3. Evans, R.W., R. Rafique, A. Zarea, et al. 2008.Nature of nontransferrin- bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13: 57-74.
4. Silva, A.M.N. & R.C. Hider. 2009. Influence of nonenzymatic post-translation modifications on the ability of human serum albumin to bind iron: implications for nontransferrin- bound iron speciation. Biochem. Biophys. Acta 1794: 1449-1458.
5. Esposito, B.P.,W.Breuer, P. Sirankapracha, et al. 2003. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102: 2670-2677.
6. von Bonsdorff, L., E. Lindeberg, L. Sahlstedt, et al. 2002. Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologicmalignancies. Clin. Chem. 48: 307-314.
7. Silva, A.M.N., X.L. Kong, M.C. Parkin, et al. 2009. Iron(III) citrate speciation in aqueous solution. Dalton Trans. 40: 8616-8625.
8. Pierre, J.L. & I. Gautier-Luneau. 2000. Iron and citric acid: a fuzzy chemistry ofubiquitous biological relevance. Biometals 13: 91-96.
9. Grootveld, M., J.D. Bell, B. Halliwell, et al. 1989. Nontransferrin- bound iron in plasma or serum from patients with idiopathic haemochromatosis. Characterization by high performance liquid chromatography and nuclearmagnetic resonance spectroscopy. J. Biol. Chem. 15: 4417-4422.
10. Adam, F.I., R.Kissner&W.H.Koppenol. 2009.Re-evaluating the role of biological ferric citrate in iron overload disease. First international conference on metal chelation in biology and medicin (MCIBAM 2009). Bath, UK. P1: 107.
11. Devanur, L.D., H. Neubert & R.C. Hider. 2008. The Fenton activity of iron(III) in the presence of deferiprone. J. Pharm. Sci. 97: 1454-1467.
12. He, X.M. & D.C. Carter. 1992. Atomic-structure and chemistry of human serum-albumin. Nature 358: 209-215.
13. Roche, M., P. Rondeau, N.R. Singh, et al. 2008. The antioxidant properties of serum albumin. FEBS Lett. 582: 1783-1787.
14. Oettl, K. & R.E., Stauber. 2007. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br. J. Pharmacol. 151: 580-590.
15. Cighetti, G., L. Duca, L. Bortone, et al. 2008. Oxidative status and malondialdehyde in beta-thalassaemia. Eur. J. Clin. Invest. 32: 55-60.
16. De Luca, C., A. Filosa,M. Grandinetti, et al. 1999. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radic. Res. 30: 453-462.
17. Ma, Y.M. & R.C. Hider. 2009. The selective quantification of iron by hexadentate fluorescent probes. Bioorg. Med. Chem. 17: 8093-8101.